Tofersen is a gene-targeted therapy for superoxide dismutase 1 (<i>SOD1</i>)-associated amyotrophic lateral sclerosis (ALS), but neurofilament light chain (NfL) may not fully capture the biological response to treatment. Here, SOD1 is linked to amyotrophic lateral sclerosis.